MS023 (MS-023) is a novel, potent, selective, and cell-active inhibitor of PRMTs (Protein arginine methyltransferases) with potential anticancer activity.

DS-437 (DS437) is a novel and potent dual PRMT5 and PRMT7 inhibitor with anticancer activity.

UNC0638 (UNC-0638) is a selective and cell-permeable inhibitor of G9a histone methyltransferase and GLP with IC50 of<15 nM and 19 nM, respectively.

XY1 is an analog of SGC707 used as a negative control of SGC-707, which is a potent, selective allosteric inhibitor of PRMT3 (IC50 = 50 nM).

TP-064 (TP064) is a novel and potent inhibitor of proteinarginine methyltransferase 4 (PRMT4) CARM1 with anticancer and anti-inflammatory activity.

GSK126 (GSK-2816126; GSK-2816126A) is a selective and SAM (S-adenosyl-methionine)-competitive inhibitor of EZH2 (Enhancer of zeste homolog 2) methyltransferase with anticancer activity.

GSK3368715 dihydrochloride (GSK-3368715; EPZ-019997; EPZ019997), the dihydrochloride salt of GSK3368715, is a potent and orally bioavailable inhibitor of type I PRMTs (protein arginine methyltransferases) with potential anticancer activity.

SGC 0946 (SGC-0946; SGC0946) is a potent and selective inhibitor of DOT1L (DOT1 Like Histone Lysine Methyltransferase) with antineoplastic activity.

BRD9539 is a potent and selective inhibitor that inhibits G9a activity with an IC50 of 6.3 μM, it also inhibits euchromatin histone methyltransferase 2 (EHMT2).

BIX01294 triHCl (the tri-hydrochloride salt of BIX01294) is a novel and potent inhibitor of G9a histone methyltransferase with IC50 of 2.7 μM in a cell-free assay.